Clin2
NCT06862726Likely a fitEnrolling by invitation

Comparing two blood thinners for atrial fibrillation

Non Valvular Atrial Fibrillation

Part of Heart & circulation clinical trials.

This study compares two commonly used blood thinners (apixaban and rivaroxaban) to see which works better for people with non-valvular atrial fibrillation, a type of irregular heartbeat. The goal is to find the safest and most effective option for preventing strokes.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
120 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • You are 18 years or older
  • You have been diagnosed with atrial fibrillation (an irregular heart rhythm)
  • You are willing to sign a consent form to join the study
  • You are not currently taking certain other medications (like some antifungals, HIV meds, or seizure meds) in the last 14 days
  • You are not pregnant or breastfeeding

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04642430Recruiting· Phase 4
Test of blood thinners comparing rivaroxaban vs apixaban

This trial compares the bleeding risk of two commonly used blood thinners—rivaroxaban and apixaban—in people with atrial fibrillation (AF). If you’re starting an anticoagulant for a new AF diagnosis, this may help doctors choose the safer option for you and others.

Victoria, British Columbia
NCT06953726Recruiting· Phase 4
Comparing apixaban and rivaroxaban for atrial fibrillation

This study compares two blood thinners, apixaban and rivaroxaban, to see which is safer and works better for veterans with atrial fibrillation (irregular heartbeat). If you're already taking one of these, the study will assign you to one of them.

West Los Angeles, California
NCT07753200Recruiting· Phase 4
Comparing two blood thinners for atrial fibrillation and heart disease

This study compares two blood-thinning medicines, edoxaban and apixaban, to see which one is better at preventing strokes and bleeding in people who have both atrial fibrillation and coronary artery disease. If you're eligible, you may receive one of these standard treatments, and the trial could help find the safer option.

Seoul
NCT06187311Recruiting· Phase 4
Rivaroxaban for atrial fibrillation patients

This trial tests two doses of rivaroxaban (15mg and 20mg) to see how well they prevent strokes in people with non-valvular atrial fibrillation, a type of irregular heartbeat not caused by a heart valve problem. It may be an option if you need blood thinners to lower your stroke risk.

Seoul
NCT06045858Not yet recruiting· Phase 3
Comparing two blood thinners for atrial fibrillation in peritoneal dialysis patients

This study tests if apixaban (a newer blood thinner) is safer and works as well as warfarin (a standard blood thinner) for patients on peritoneal dialysis who have atrial fibrillation (an irregular heartbeat). It aims to reduce the risk of stroke and bleeding.

NCT07237308Not yet recruiting· Phase 4
Two blood thinners compared for stroke with atrial fibrillation

This study tests whether a common blood thinner (apixaban) alone is as safe and effective as combining it with another drug (clopidogrel) to prevent future strokes in people who have both atrial fibrillation and narrowing in the arteries leading to the brain. It aims to find the best way to reduce stroke risk while minimizing bleeding.

Hear when a new Non Valvular Atrial Fibrillation trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.